Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information In appraisal.
Process STA Standard
ID number 6335

Provisional Schedule

Expected publication 18 December 2024

Email enquiries


Key events during the development of the guidance:

Date Update
11 December 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and it is now anticipated to begin in early March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
27 October 2023 - 20 November 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
20 October 2023 Following a request received from the company, NICE will be undertaking an evaluation of Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]. The evaluation is expected to start during early-October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during late-November 2023.
20 October 2023 In progress

For further information on how we select topics for development, please see our page about topic selection